IGM Biosciences, Inc. (IGMS)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Engineered Immunoglobulin M Antibodies	2.13M	Log In
Engineered Immunoglobulin M Antibodies Growth	99.25%	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	2.13M	Log In
United States Growth	99.25%	Log In